<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01062698</url>
  </required_header>
  <id_info>
    <org_study_id>2009-A00753-54</org_study_id>
    <nct_id>NCT01062698</nct_id>
  </id_info>
  <brief_title>Trial and Cost Effectiveness Evaluation of Intra-arterial Thrombectomy in Acute Ischemic Stroke</brief_title>
  <acronym>THRACE</acronym>
  <official_title>The Contribution of Intra-arterial Thrombectomy in Acute Ischemic Stroke in Patients Treated With Intravenous Thrombolysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <brief_summary>
    <textblock>
      THRACE is a controled, multicenter and randomized trial.&#xD;
&#xD;
      The primary objective of this study is to determine whether a combined approach intravenous&#xD;
      thrombolysis (IV) + Mechanical thrombectomy is superior to the reference treatment with IV&#xD;
      thrombolysis alone, in the 3 hours of onset of symptoms in patients with occlusion of&#xD;
      proximal cerebral arteries and with a neurological impairment accident (National Institutes&#xD;
      of Health Stroke Scale [NIHSS] â‰¥ 10).&#xD;
&#xD;
      The second objective is to determine the cost-effectiveness of this procedure compared to the&#xD;
      standard (IV thrombolysis). The assumption is that the combined approach, by improving the&#xD;
      clinical outcome and speed recovery, allows for lower overall costs to the IV thrombolysis in&#xD;
      3 months and less than or at worst neutral to 1 year.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Efficacy&#xD;
  </why_stopped>
  <start_date>June 2010</start_date>
  <completion_date>March 2016</completion_date>
  <primary_completion_date>December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Rankin Score (mRs )</measure>
    <time_frame>3 months after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (Euroqol EQ-5D)</measure>
    <time_frame>3 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Score</measure>
    <time_frame>3 months after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">412</enrollment>
  <condition>Cerebral Stroke</condition>
  <condition>Cerebrovascular Accident</condition>
  <arm_group>
    <arm_group_label>IV thrombolysis + thrombectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IV thrombolysis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alteplase (rt-PA)/Actilyse</intervention_name>
    <description>Injection of 0.9 mg/kg for 60min with an initial 10% bolus injection.</description>
    <arm_group_label>IV thrombolysis</arm_group_label>
    <arm_group_label>IV thrombolysis + thrombectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Mechanic thrombectomy (MERCI, PENUMBRA, CATCH, SOLITAIRE)</intervention_name>
    <description>Mechanic thrombectomy</description>
    <arm_group_label>IV thrombolysis + thrombectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  10&lt;=NIHSS Score=&lt;25&#xD;
&#xD;
          -  Symptoms onset less than 4 hours&#xD;
&#xD;
          -  Occlusion of the intracranial carotid, the middle cerebral artery (M1) or the upper&#xD;
             third of the basilar&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications for intravenous thrombolysis&#xD;
&#xD;
          -  Occlusion or stenosis of the pre-occlusive cervical internal carotid artery&#xD;
             ipsilateral to the lesion&#xD;
&#xD;
          -  Any cause local prohibiting femoral catheterization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Serge Bracard, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Hospital Nancy France (HNF)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Hospital Nancy (Central HNF)</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>February 3, 2010</study_first_submitted>
  <study_first_submitted_qc>February 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2010</study_first_posted>
  <last_update_submitted>July 20, 2017</last_update_submitted>
  <last_update_submitted_qc>July 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central Hospital, Nancy, France</investigator_affiliation>
    <investigator_full_name>Directeur de la Recherche et de l'Innovation</investigator_full_name>
    <investigator_title>Professor Serge BRACARD</investigator_title>
  </responsible_party>
  <keyword>mechanical Thrombectomy</keyword>
  <keyword>CVA (Cerebrovascular Accident)</keyword>
  <keyword>Cerebrovascular Accident, Acute</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

